Embed Size (px)
Citation preview
Multidisciplinary Innovation in Healthcare and Life Sciences
HEALTHTEC CLUSTER
CONTENTS 1 Foreword
2 Harwell’s outstanding organisations
4 History
6 Vision for the future
8 A driving force for life science innovation
10 Open access facilities 11 Diamond Light Source 12 Central Laser Facility 13 ISIS 14 The Rosalind Franklin Institute 15 Vaccines Manufacturing and Innovation Centre (VMIC) 16 MRC Harwell Institute 17 Public Health England 18 Research Complex at Harwell 19 European Space Agency 20 Spectroscopy at RAL Space 21 Satellite Applications Catapult
22-36 Harwell HealthTec Organisation listings (listed alphabetically)
38 Collaborative advantage 39 Cross-disciplinary working
40 Harwell tomorrow – property development
42 Life at Harwell
44 Investment, funding sources and business support
45 Travel and access
47 Contacts
HARWELL CAMPUS
700acres
6000+people
200+ organisations
harwellcampus.com
HEALTHTEC / LIFE SCIENCES
1250+people
TALENT from over
60 countries
58organisations
onsite
100+member organisations
in wider cluster network
FOREWORDI participated in the “Accelerating Healthcare Innovation” conference at Harwell with Tim Peake and this highlighted the many collaborations required across multiple disciplines to keep humans healthy in space and on Earth.
Indeed advancements in all areas of healthcare are increasingly dependent on the cross fertilisation of ideas across different fields and this is one reason why I am so excited by the development of the HealthTec Cluster at Harwell. I am sure that this new Cluster will quickly become a world leading healthcare innovation hub exploiting the inter-disciplinary collaboration between physical & life sciences.
Within healthcare, Harwell already hosts 1,250 people across 58 organisations, many utilising the capabilities of the large “open access” facilities such as the Diamond Light Source Synchrotron or the Central Laser Facility’s “Octopus” for drug discovery and the development of biocompatible materials. Harwell is also home to Public Health England’s Centre for Radiation, Chemical and Environmental Hazards and the MRC’s Harwell Institute as well as the ISIS neutron & muon source.
The £103m investment in the new Rosalind Franklin Institute announced in February 2017, to be located at Harwell with up to 240 scientists linked to 10 major universities, will create a unique centre bringing together the UK’s strengths in the physical sciences, engineering and life sciences.
Harwell is already home to a thriving ecosystem of innovative companies across a broad spectrum of emerging pharmaceutical/biotech, medtech, diagnostic, digital health and other areas of HealthTec .
I hope that many of you will join us here and become part of this exciting, fast growing innovative cluster.
Professor Sir John Bell Regius Professor of Medicine University of Oxford
1
HARWELL: AN OUTSTANDING CENTRE FOR SCIENTIFIC AND INDUSTRIAL INNOVATION
1
17
10
13
2
6
1116
14
3
19
7
12
18
21
15
4
8
5
9
12
20
19
ISIS3
RAL Space7
Rutherford Appleton Laboratory STFC
11
Fermi Gate Development
Residential Complex15
Central Laser Facility4
Satellite Applications Catapult8
Rosalind Franklin Institute16
The Quad12
VMIC20
Public Health England1
Research Complex at Harwell5
European Space Agency9
Zephyr Building13
The Extreme Photonics Applications Centre (EPAC)17
Agilent21
Medical Research Council2
Diamond Light Source6
Scientific Computing Data10
Genesis Building14
Oxford Nanopore Technologies18
2 3
2010’s 2016
HeathTec Cluster launch
2017
Rosalind Franklin Institute announced
2018
Official opening of eBIC at Diamond – a national facility for cryo-electron microscopy
2019
£67m Vaccines manufacturing and Innovation Centre announced
2019
Oxford Nanopore launch automated manufacturing facility
2019
£67m Vaccines Manufacturing and Innovation Centre announced
2019
Building of the Rosalind Franklin Institute commences
2010’s 2010
MRC researchers show that the FTO gene leads to obesity
2010
Research Complex at Harwell opened
2012
Non-invasive biopsy technique discovered at the Central Laser Facility is viable for diagnosing breast cancer
2013
The University of Oxford and Harwell formalise a partnership for discovery and innovation
2013
Active Laser Facilities at CLF expanded
2013
The Satellite Applications Catapult is established
2000’s 2006
ISIS Neutron Source conducts the first experiment to develop glass to replace bone transplants
2006
Science and Innovation Minister Lord Sainsbury announces £26m investment in a new Research Complex at Harwell (RCaH)
2007
STFC is founded taking control of RAL
2007
The £260m Diamond Light Source is opened by Queen Elizabeth II
1970’s 1975
NPRB opens its HQ at Harwell – later to become Public Health England
1975
Frozen Embryo and Sperm Archive is established by researchers at MRC
1976
Central Laser Facility opened
1980’s 1985
MRC researchers discover genetic imprinting in mice1960’s
1961
Dr Mary Lyon working with the MRC, discovers X chromosome inactivation
1963
Work by the MRC Harwell Radiobiology Research Unit leads to ban on the atmospheric testing of atomic weapons
1950’s 1957
Rutherford Laboratory is established to handle high energy physics work
1940’s 1947
Harwell’s first tenant, Medical Research Council (MRC), sets up its Radiology Unit
2020’s 2020
£30m Nucleic Acid Therapy Accelerator announced
2020
£80m Extreme Photonics Application Centre announced
2020
Campus designated a ‘Life Sciences Opportunity Zone’ (LSOZ) by the Office for Life Sciences. Working with the DIT, Harwell is one of just six UK LSOZs supported to attract inward foreign investment
2021
Rosalind Franklin Institute due to launch
2021
Vaccines Manufacturing and Innovation Centre (VMIC) due for completion
A long rich history of innovation in healthcare.
HISTORY
44 5
OUR VISIONFOR THE FUTUREThe Harwell HealthTec Cluster is a world-leading healthcare innovation hub founded on inter-disciplinary collaboration between physical and life sciences. Located within the Golden Triangle of Cambridge, London and Oxford in the heart of England, Harwell Campus is set to play an increasingly important role at the centre of this sector.
By connecting pharma, biotech, medtech and agritech sectors with public health organisations and members of the EnergyTec and Space Clusters on campus, new insights in technology are shared, leading to innovative solutions and disruptive technologies. Our globally unique platform and state of the art technologies and applications help accelerate research towards the clinic and into commercial outputs.
Harwell undertakes research with a specific focus on drug discovery, ageing and environmental impact on human health, leading to the generation of novel medical devices and materials, diagnostic tools, advanced therapeutics, medical imaging and digital health
technologies, drug design solutions and data analytics. These advancements in healthcare are driven by the cross fertilisation of knowhow and techniques, an exceptional combination of national facilities, industry and academia, and a vibrant and colligate ecosystem of highly skilled people and globally unique technologies. Recent additions to the campus including the Rosalind Franklin Institute, Vaccines Manufacturing and Innovation Centre and the Nucleic Acid Therapy Accelerator, together with a 10 year government designation as a ‘Life Sciences Opportunity Zone’, will strengthen this bionetwork and create an even more integrated and comprehensive hub in which large and small companies can flourish, and new collaborations can be struck with brilliant academics and public sector researchers at the leading edge of science. In addition to the Diamond Light Source and Rutherford Appleton Laboratory, these facilities will act as anchors to attract inward investment and build a critical mass of researchers in specialised fields, including precision medicine, advanced therapies and AI.
The campus is set to grow
rapidly with active engagement
with the Department for
International Trade and wider
Oxfordshire ecosystem.
Business support from campus
management, business
incubators and the Science
and Technology Facilities
Council will continue to help
companies seize the benefits of
“Collaborative Advantage” with
multidisciplinary collaboration
across different sectors being
encouraged and actively
facilitated, not only across
campus but also nationally and
internationally. Our plans also
include the development of a
further business accelerator
that can work alongside
universities, Harwell facilities
and companies to rapidly exploit
and commercialise advances in
research and technology.
“ ...A CREATIVE AND INSPIRATIONAL ENVIRONMENT, BACKED UP BY COMMERCIAL KNOW-HOW...”
The HealthTec and life sciences cluster benefits from the very strong specialist investor network that exists in Oxfordshire and will reach out more broadly to the southeast and internationally. The vision of the physical growth of the cluster on the campus is guided by an overall masterplan that ensures coherent development. Harwell Campus is already working alongside HealthTec Cluster organisations that are expanding their operations by offering them a range of accommodation options, including bespoke solutions, within a flexible and attractive environment. The overall masterplan includes 750,000 sq
ft of specialist accommodation for the Life Sciences community. HealthTec will operate alongside the highly successful Space Cluster at Harwell, exploiting common support mechanisms and benefiting from the crossover of knowledge, skills and disruptive technologies with Space Cluster organisations that include ESA’s European Centre for Space Applications and Telecommunications (ECSAT), the Satellite Applications Catapult and RAL Space. Likewise the Cluster will benefit from engagement with the growing EnergyTec Cluster and proposed Living Laboratory, which will provide a real-life
environment where systems, services and processes can be safely tested and evaluated, de-risked, commercialised and integrated with the needs and ambitions of the local community.
The HealthTec Cluster provides a creative and inspirational environment, backed up by commercial know-how that can ensure that innovation gets translated into real impact and increased productivity.
Dr Barbara GhinelliCampus Business Development Director
6 7
GSK has benefited from engagement with the specialists at the world leading research facilities at the Harwell Campus. We have found the experts there to have an industry friendly approach to working with us, and have worked closely with facilities like Diamond to accelerate innovation within our drug discovery programmes. We view the growing HealthTec cluster at Harwell as playing an increasingly important part in the UK’s innovation landscape.
Dr Malcolm SkingleDirector of Academic Liaison, GSK
The UK has a world renowned heritage in life sciences. Our life science sector has a global impact on societal health challenges such as the ageing population, cancer and sedentary lifestyles. Life science innovation and IP creates jobs, facilitates healthcare and augments growth.
Adjacent is the world-class University of Oxford, together with excellent links to top universities around the UK, many of whom have a physical presence on the Campus
• Oxford University ranked World No.1 in clinical and health and World No.3 in life sciences
• Rosalind Franklin Institute linked to 10 major universities
• 30+ universities have people on site
Critical mass of companies and science
• Over 200 R&D related organisations on site
• Over 250 companies in Oxfordshire’s BioPharma Cluster
An outward-facing culture and engagement with industry
• Leading industry engagement with Diamond’s customer base including; GSK, AstraZeneca & Pfizer
• 60 nationalities on site every day
A multi-talented workforce
• 49% of Oxfordshire workforce educated to degree level, well above the national average of 36%
World-class core science infrastructure
• Diamond, CLF, ISIS, MRC
• Strengthened by arrival of RFI
Pro-active collaboration
• Regular ‘Connect Harwell’ events actively foster the collaborative advantages available on site and other cluster-specific networking events
Accommodation and expansion space
• 700 acre site
• Labs, offices & technical space
– Further amenities underway & planned
– New restaurant and 2nd hotel
• Reserve land alongside for your expansion
Access to finance
• Top tier funds based locally (UKI2S, Invesco, OSI)
• Multiple sources of established early stage money
An attractive place to live and work
• Hundreds of affordable homes being built on site for sale or rent
Dr Malcolm Skingle
98
A DRIVING FORCE FOR LIFE SCIENCE INNOVATION
8 9
Diamond Light Source is the UK’s synchrotron, an advanced research facility. It harnesses the power of electrons to produce light 10 billion times brighter than the sun that scientists can use to study anything from fossils and fuels to viruses and vaccines.
Diamond plays a major international role in biomedical research. A significant amount of Diamond’s scientific output comes from scientists who are working on a wide range of challenges from designing drugs to combating infectious diseases and treating cancer, to finding new solutions to the increasing challenge of drug resistance.
OPEN ACCESS FACILITIESHarwell is home to the UK’s world-leading national physical sciences laboratories representing an investment of over £2 billion to date.Capabilities range from genetics and genomics, cellular and structural biology to pharmacology, big data, space technologies, advanced materials and engineering. These rare “open access” facilities and associated skills, provide a powerful platform to help accelerate innovation using leading-edge new technologies and applications, taking advantage of opportunities for collaboration between partners from different disciplines to inspire fresh thinking.
Please come and let us surprise you by just how much is on offer at Harwell.
Genuinely “open access” facilities looking to engage in solving complex problems for both academics and companies.
1,200 STFC staff support the work of 10,000 scientists and engineers.
DIAMONDLIGHTSOURCE
AstraZeneca has been closely involved with Harwell for many years, not only with the Diamond Light Source for advanced X-ray crystallography but also increasingly in exploring multiple collaborations involving new disciplines and technologies.
Dr Chris PhillipsAssociate Director, AstraZeneca Our pioneering research is greatly enhancing
our ability to apply our structure-based approach to drug discovery across a wide range of GPCR targets with strong clinical validation, but which have proved difficult or impossible to access previously. Access to Diamond’s crystallography beamlines remains critical for our work and the synchrotron’s developments in areas such as microfocus crystallography and membrane protein research will further strengthen the UK’s position as a leading contributor to structural biology research globally.
Dr. Andrew S. DoréDirector, Head of Crystallography, Sosei Heptares
diamond.ac.uk
A view of the VMXi end-station at Diamond during data collection. This shows a standard in situ crystallisation plate held on a goniometer while exposed to x-rays. This beamline is capable of collecting thousands of individual datasets every day. The analysis of these x-rays gives the scientist the information required to build a three dimensional picture of the chemical structure of the samples.
Some of the areas covered include:
• Infectious diseases• Cancer research• Neurodegenerative research• Drug resistance • Drug design• Vaccine design• Biomaterial design and imaging• Radiation biology
The facilities and capabilities accessible through Diamond include:
• Protein crystallography for containment level 3 pathogens - unique in the world
• First in the world national facility for single particle and tomography
• XChem facility - fragment based drug discovery with high throughput (>700 crystals per day)
• Microfocus crystallography able to handle tiny and fragile samples
• X-ray microscopy at the cellular and sub-cellular level. This enables users to close the resolution gap that exists between electron microscopy and conventional light microscopy, allowing the acquisition of tomographic data from both native and fluorescent-labelled samples
• X-ray Free Electron Laser (X-FEL) techniques
1010 11
The CLF’s wide ranging applications include experiments in physics, chemistry and biology, accelerating subatomic particles to high energies, probing chemical reactions on the shortest timescales and studying biochemical and biophysical processes critical to life itself.
From advanced, compact, tuneable lasers that can pinpoint individual particles to high power laser installations that recreate the conditions inside stars, a vigorous development programme ensures that the CLF’s facilities maintain their international competitiveness.
clf.stfc.ac.uk
Artemis
Artemis is the CLF’s facility for ultrafast XUV science. Experiments on Artemis investigate ultra-fast electron dynamics in condensed matter and gas-phase molecules.
Gemini
Gemini is an extremely high power, ultra-short pulse laser system delivering dual beams of 15 J, 30 fs laser pulses, at a rate of one shot every 20 seconds, focused to intensities in excess of 1021 W cm-2.
Octopus
Octopus (Optics Clustered to OutPut Unique Solutions) imaging cluster offers a range of imaging techniques including multidimensional single molecule microscopy, confocal microscopy and optical profilometry.
Ultra
Ultra combines laser, detector and sample manipulation technology to probe molecular dynamics on the femtosecond to microsecond timescales.
Vulcan
Vulcan is a petawatt laser system, used for experiments researching High Energy Density (HED) science including fusion energy, electron and ion acceleration, laboratory astrophysics and plasma physics.
At the CLF there are state-of-the-art laser imaging systems suitable for innovative life and physical science research.
CENTRAL LASER FACILITYThe Central Laser Facility (CLF) at the STFC Rutherford Appleton Laboratory is one of the world’s leading laser facilities, providing scientists from the UK and Europe with an unparalleled range of state-of-the-art laser technology and expertise across the scientific disciplines.
The use of the Octopus imaging suite at the Central Laser Facility (CLF) for confirmation of expression and membrane protein trafficking serves as a key step for membrane protein QC. A recent study is working towards the elucidation of the mTOR structure. This collaboration brings together CLF’s experience and technology, along with Evotec’s structural biology platform for elucidating signalling pathways and to identify new paths for drug discovery.
Richard Hitchman Evotec
The ISIS neutron and muon source carries out over 1,000 experiments each year into subjects ranging from the environment, pharmaceuticals and healthcare, through to nanotechnology and beyond. ISIS has also been used to study, at the molecular level, the mechanism of antimicrobials targeted at particular fungal infections.
The use of neutrons and muons as probes bestows capabilities complementary to those of synchrotron sources like Diamond, which uses photons of light. This includes sensitivity to biological material through the signatures of hydrogen and carbon.
The ISIS neutron and muon source supports a national and international community of more than 3,000 scientists for research into subjects ranging from the environment, pharmaceuticals and healthcare, through to nanotechnology and beyond.
An impact on many fields:
• Infectious diseases• Cancer research• Antibody research• Protein structural biology• Drug design• Toxicity studies• Surface imaging
ISIS is a world-leading centre for research in the physical and life sciences at the STFC Rutherford Appleton Laboratory. The ISIS suite of neutron and muon instruments gives unique insights into the properties of materials on the atomic scale.
ISIS
isis.stfc.ac.uk
This seminal work highlights the power of neutron scattering as a tool for understanding very complex but medically relevant systems. The unique partnership between neutrons and hydrogen has enabled us to probe the effects of cisplatin drug on the structure and dynamics of intracellular water in human cancerous cells. We hope the results are a step towards designing more effective breast cancer treatments.
Dr Victoria Garcia SakaiInstrument Scientist, OSIRIS
Signing of a Memorandum of Understanding, Dr Andrew Taylor (Executive Director of the National Laboratories) and Professor Liu Conqiang (Vice President of the National Science Foundation of China), Royal Greenwich Naval College, London 2015.
12 13
The Rosalind Franklin Institute is a national research institute, funded by UK Research and Innovation through the Engineering and Physical Sciences Research Council. Our mission is to bring about transformative changes in life science through interdisciplinary research and technology development.
Creating new drugs has never been slower or more expensive, but need is growing faster than ever – with antimicrobial resistance increasing, escalating healthcare costs; an ageing population; the growing impact of mental illness, or of intractable diseases such as dementia, and threats to food security.
The substantial challenges faced by the life sciences sector means that the current business model for the development of new treatments is fast becoming unsustainable. Yet the legacy of advances in life science over recent decades is that we have greater insight into the root causes of disease than at any time in our history – the potential is huge for technology to advance and impact lives around the world.
Our work is focused into five complementary themes, which together will produce technologies which allow us to see the biological world in new ways, from single molecules to entire systems. This insight will speed up drug design and development, and push forward our understanding of human health and disease.
‘A Franklin project is defined by its ability to move the state of the art forward by a factor of ten. We seek to develop world unique tools, which offer both novelty and utility – our technologies must meet a defined need in both the academic and industrial sector.’
‘Working with both industrial and academic partners from across the UK, we will foster interdisciplinary research with real impact.’ – Professor James Naismith.
Operating on a ‘hub and spokes’ model, the Institute central hub is located at the Harwell Campus. Opening in 2021, the hub will house a unique portfolio of scientific tools and researchers from both industry and academia. Equipment and researchers will also be located in spokes distributed throughout our partner network of ten leading UK universities.
The Institute is open to new collaborations and partnerships with both academia and industry – for more information please visit www.rfi.ac.uk or contact the team at [email protected].
Services provided by VMIC:
GMP Compliant manufacture (FDA and MHRA)
• GMP Cell and Viral banks
• GMP bulk product (scale 1 – 1000 L)
• GMP fill and finish (scale 100 – 100,000 vials)
• QA/QC/QP and batch release by VMIC
Manufacturing development
• Provide vaccine P&AD expertise
• Facilitate transition of vaccines into the clinic
• Provide rapid economic manufacture clinical material
Emergency response and stockpile capability
• Ability to respond immediately to a threat that constitutes an emergency
• Trained staff and compliant facilities ready to operate
• Preparedness through internal protocols and external MOU’s
Knowledge Transfer
• Development of highly skilled workforce
• Provision of training in vaccine development and GMP
• Generation of new IP
ROSALIND FRANKLIN INSTITUTE VACCINES MANUFACTURING AND INNOVATION CENTRE (VMIC)
Structural Biology – improving sample preparation and delivery, detector R&D, and common standards for sample exchange
Large Volume Electron Tomography will enable the molecular mapping of whole cells, and cell:cell interactions.
C100: detector development for low energy cryo-EM will open up cryo-EM to a global audience.
Protein Production UK will revolutionise how protein samples are produced, stabilised, delivered and transferred including production of nanobodies and macrocyclic compounds.
Next Generation Chemistry for Medicine – speeding up drug discovery and improving efficient translation.
Protein editing methodologies and AI-driven drug discovery capabilities, leading to novel medicines, enhanced analytics, integrated approaches to discovery and translation, and ultimately reduced costs.
Biological Mass Spectrometry – integration of data from omics platforms – omic data fusion; next generation of instruments and detectors.
Unique platforms to deliver enhanced structural characterisation, super high resolution imaging of large molecules, ultrafast high throughput mass spectrometry, and imaging for an unprecedentedly broad range of untargeted biochemically relevant species in tissues. Hundreds of new tissue-derived biomarkers identified with these technologies will result in the early detection of chronic diseases and identification of novel druggable targets.
Time-resolved correlated imaging – moving from static to time-resolved study of drug take-up.
Pulse-mode ptychography will enable structural studies of smaller molecules (<50kDa) in native environments.
Chromatic correction will enable electron microscopy in thicker biological samples.
Artificial Intelligence and Informatics
AI and informatics is applied across all Franklin themes to manage large data sets, auto-mating data analysis, and highlighting results of interest to researchers.
VMIC is currently under construction at Harwell Campus in Oxfordshire. As the first of its kind in the UK, it will help collaborators develop and manufacture vaccines for clinical use from prophylactic and therapeutic vaccines, predominantly relating to infectious and emerging diseases; utilising and enhancing a variety of platforms including live viral vectors, nucleic acids, attenuated viruses and bacteria and subunit vaccines.
VMIC will largely focus on novel and innovative manufacturing technologies, including viral vector vaccines and are playing a critical role in the UK response for Covid-19.
rfi.ac.uk
vmicuk.com
14 15
MRC HARWELL INSTITUTE
mousephenotype.org
The MRC Harwell Institute is at the international forefront of the use of mouse genetics to study the relationship between genes and disease, from the earliest stages of development to diseases of ageing. They are a key player in the International Mouse Phenotyping Consortium (IMPC), a global project that aims to find a function for every protein-coding gene in the mouse genome and make the data freely available to other scientists via the IMPC portal.
Their international datacentre collects and quality controls large amounts of biomedical research data from the international partners of IMPC and develops statistical analysis and methods of on-line display and searches. They also have a portfolio of research programmes to advance medicine through cutting-edge research into the genetic basis of disease.
har.mrc.ac.uk
gov.uk/government/
organisations/public-
health-england
phe-protectionservices.
org.uk
THE AREAS OF RESEARCH AT THE MRC HARWELL INSTITUTE INCLUDE:Large-scale functional genomics
• International Mouse Phenotyping Consortium (IMPC)
• CRISPR/Cas9
Lifetime studies
• Disease model discovery
• Genetics and pathobiology of deafness
• Genetics of type 2 diabetes
• Neurobehavioural genetics
• Genetic disorders of sex development
• Cilia, development and disease
• Neurodegenerative disease
• Neurological disease
Translational studies
• Genetics of otitis media
• Genetics of type 2 diabetes
Data analysis and dissemination
• Biocomputing
• Statistical genomics
MRC Harwell also delivers many services including Genome Editing Mice for Medicine (GEMM) a bespoke genetically modified mouse service for UK Science. Other services include genome engineering, husbandry and phenotyping, pathology and bioimaging, and archiving and distribution.
PUBLIC HEALTH ENGLAND
Public Health England (PHE) exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. As an executive agency, sponsored by the Department of Health, PHE is, amongst other things, responsible for:
• Making the public healthier by encouraging discussion, advising government and supporting action by local government, the NHS and other people and organisations
• Protecting the nation’s health through the national health protection service, and preparing for public health emergencies
• Researching, collecting and analysing data to improve our understanding of health and come up with answers to public health problems
• Helping local authorities and the NHS to develop the public health system and its specialist workforce
PHE’s radiation protection functions have been located on the Harwell site since the 1970s, and the Centre for Radiation, Chemical and Environmental Hazards is now responsible for investigating the potential effects of environmental factors on human health for the UK.
State-of-the art analytical facilities, cell and animal models, specialist exposure facilities and unique technologies, are used to assess an array of potential environmental hazards, such as chemicals, pollutants, nano-particles and moulds, to determine whether they can adversely impact human health in different settings (open spaces, industry or homes). In particular, the low-dose chronic irradiation facility, one of just six such facilities globally, is used to investigate the mutational and non-mutational effects of radiation on human cells, enabling new perspectives into the interaction between radiation and human health. Similarly, other unique facilities offer real-time measurements of light, helping researchers to establish how the duration and wavelength of light can affect biological processes, circadian rhythms, safety and human health. PHE is also at the forefront of developing an epigenetic-based method of measuring and monitoring human health, using AI and DNA methylation datasets to identify biomarkers of human age.
PHE meets its responsibilities through the development and conduct of world-class science, provision of knowledge and intelligence, advocacy and advice, through facilitating partnerships and by providing specialist public health services. Specialist radiation protection professional training and advice, modern laboratories for radiation biology, toxicology and nanotoxicology research, and radiation dosimetry and monitoring services, are used to provide up-to-date evidence that translate into effective health protection services.
PHE’s Harwell site location provides us unique opportunities to establish and develop multidisciplinary collaborations to address many of the current concerns in environmental and wider public health.
Simon BoufflerHead of Radiation Effects Department, Public Health England’s Centre for Radiation, Chemical and Environmental Hazards (CRCE)
16 17
The European Centre for Space Applications and Telecommunications (ECSAT) is the most recent addition to the European Space Agency’s operational sites across Europe.
Approximately 100 people are based as ESA’s ECSAT centre in Harwell supporting activities related to telecommunications, integrated applications, climate change, technology and science. ECSAT focuses on the development of commercial space-based products and services, downstream applications and the ‘spin-out’ of space into non-space sectors. This includes the use of technology and micro-gravity research developed for human space flight.
Harwell Campus is also home to one of ESA’s Business Incubation Centres. The ESA BIC at Harwell is managed by STFC and provides an opportunity for startups to access world class scientific facilities and research. More than 55 startups have been nurtured at the BIC since 2011, addressing a wide range of markets.
esa.int/ESA
Many of the most important advances in science take place at the interfaces between traditional disciplines and frequently used large central facilities. The Research Complex at Harwell (RCaH) provides the environment and facilities for researchers in the life and physical sciences to undertake research across such traditional barriers and encourages synergy between these areas of UK research excellence. It is especially targeted at researchers who will conduct work at the Central Laser Facility, Diamond and ISIS and other shared facilities on the Harwell Campus.
RCaH offers access to a Biophysical Facility that is equipped with state-of-the art instrumentation, run by a specialist who can train users in sample preparation, use of the equipment and data analysis, or alternatively can analyse users’ samples and provide them with experimental data. The facility also offers access to well-maintained cell and tissue culture rooms, with supporting equipment such as microbiological safety cabinets (Class II), CO2 incubators, and microscopy. In addition, several research groups based in the RCaH offer facilities that can be accessed by both academic and industrial users.
Facilities offered by the RCaH research groups range from protein production and antibodies (PP-UK facility), membrane protein production and characterisation (MPL group), laser-coupled microscopy (CLF), surface analysis by X-ray photoelectron spectroscopy (XPS facility), to a computational integrated suite for protein structure analysis (CCP-4 and CCP-EM).The Central Laser Facility’s ULTRA and Octopus facilities in RCaH are used for research across the life and physical sciences, for example studying how DNA is able to repair itself after damage, investigating how the growth of cells is controlled in health and disease, looking at how molecules capture light, and watching catalysts function in real time.
RCaH Biophysical facility - available techniques
• Analytical ultracentrifugation (including the latest model of the Beckman AUC Optima)
Determining molecular interactions and hydrodynamic properties. Applications include: the determination of molecular weight, hydrodynamic size and shape, sample purity, concentration dependent behaviour, and self association.
• Isothermal Titration Calorimetry (Malvern iTC200).
Determining the affinity, stoichiometry, and thermodynamic properties of an interaction (enthalpy, entropy), and the effects of mutations on binding.
• Stopped-flow fluorimeter (Tgk SF61DX2)
Determining the chemical kinetics of fast reactions in solution.
• Surface Plasmon Resonance (BiaCore T200)
Determining molecular interactions,including quantitation, kinetics and affinity, and Epitope mapping.
• Size-Exclusion Chromatography Multi Angle Light Scattering (AktaPure 25 coupled to a DAWN HELEOS detector)
For characterisation of membrane| protein complexes, and pre crystallisation samples checks.
rc-harwell.ac.uk
THE RESEARCHCOMPLEX AT HARWELL
EUROPEANSPACEAGENCY
We are all struck by the tremendous opportunities for innovation that are arising from the cross-over of research in Space, Life Sciences and Physical Sciences. This is creating exciting prospects for the commercialisation of research in three areas in particular: the effects and mitigation of ageing; environmental impacts on human health; and new materials for the treatment of medical conditions.
Magali VaissiereDirector of Telecommunications & Integrated Applications, Head of ECSAT Centre
100 ESA employees
are based in Harwell
18 19
sa.catapult.org.uk
The Satellite Applications Catapult is transforming the way the world uses satellite technology, enabling new business and improving people’s lives. Within the healthcare sector, we are working to maximise the contribution of satellites wherever possible and to boost the opportunities for UK organisations globally. This is in response to a shift in the day-to-day provision of healthcare, whereby digital solutions are playing an ever-greater role. Satellite technology can improve outcomes overall for health and wellbeing by enhancing and enabling both treatment and supporting services. Additionally, because satellites offer global coverage, they offer the opportunity to reduce local healthcare inequalities.
As just one of many application areas, the Catapult is using satellite communications to enhance healthcare provision in remote rural areas by boosting connectivity where robust and reliable service is essential – for example to deliver screening for inflammatory bowel disease, ultrasound scanning for strokes and diagnosis of foot ulcers in diabetics. “Always Connected” medical screening vehicles use satellites to send images from mobile breast screening vans to an NHS picture archiving and communications service (PACS). The service also provides access to appointment systems and key software applications. Based on this, several NHS Trusts are already moving to paperless working on their screening vans, with the objective of rolling this out nationwide and extending it to other programmes, such as MRI screening.
SATELLITE APPLICATIONS CATAPULT
ralspace.stfc.ac.uk
SPECTROSCOPY AT STFC RAL SPACERAL Space Spectroscopy Group develop unique and novel laser-based systems for environmental and atmospheric monitoring targeting very high performance needs.
This activity encompasses the development of concepts, demonstrators, prototypes, processing methods and algorithms, which leads ultimately to field deployment. The urgent need for novel high performance measurement systems relates to the threat posed by climate change and air quality and their understanding and possible mitigation. Instrument concepts developed by the team encompass in-situ miniature laser spectrometers, laser isotopic analysers, spectroscopic lidar, open-path laser spectrometers, and laser heterodyne spectro-radiometers targeting greenhouse gas emission monitoring and pollutants and precursors monitoring.
One example of the group’s work is the concept of a quantum cascade laser heterodyne spectrometer that has been developed over the last few years and is currently being deployed as part of an international field measurement campaign taking place at the Finnish Arctic Research Station. The campaign aims to assess, cross-compare, and validate novel instrumentation for greenhouse gas emission monitoring to be part of the forthcoming global greenhouse gas observing system encompassing ground, airborne and space monitoring sensors.
•MEASURE AIR QUALITY
•GUIDE EMERGENCY SERVICES
•TRACK MOVEMENT OF ORGAN
•MANAGE TRAFFIC TO SPEED UP
•HELP THE PARTIALLY SIGHTED
AND BLOOD DONATIONS
EMERGENCY RESPONSE TIMES
NAVIGATE CITIES
•CONNECT CARS TO EMERGENCY SERVICES
•CONNECT MEDICAL MONITORS•MONITOR PEOPLE AFFECTED BY DEMENTIA
•DETECT ACCIDENTS IN RURAL AREAS
•PROVIDE QUICK RESPONSES FOR RURAL PATIENTS
SATELLITES HELPING THE HEALTH SECTORSATELLITES CAN...
20 21
INNOVATIONAT HARWELL
Harwell is home to a number of innovative healthcare companies which benefit from the unique multi-disciplinary environment on the Harwell Campus, where they can forge collaborations with other companies with complementary skills and with the main “open access” facilities and other centres that are part of the HealthTec Cluster in order to accelerate the development of their products.A few examples are illustrated in the following pages.
accentus-medical.com
‘The collaborative and multi-disciplinary ethos of the Campus also serves to build resilience and the flexibility to rapidly address emerging challenges, the importance of which has been all too apparent in the Covid19 crisis’
Dr Barbara GhinelliDirector, Clusters and Campus Business Development UKRI Science and Technology Facilities Council
22
3dmagination.eu
With established expertise in 4D time-resolved laboratory and synchrotron X-ray computed tomography, 3Dmagination provides advanced R&D services and custom-built training in 3D and 4D imaging for industrial applications, with a major part in healthcare. Our powerful 3D strain mapping technology is implemented and commercialised into the world-wide Thermo Scientific™ Amira-Avizo imaging software and benefit different scientists working in the field of biomechanics.
3DMAGINATION
Accentus Medical builds on over 30 years of expertise in research & development of surface coating technologies delivering new surface solutions for commercialisation within the global medical device industry. The company’s origins go back to the UK Atomic Energy Authority at Harwell and its expertise in materials and surface coatings/treatments. The company’s principal technologies include Agluna® surface treatment incorporating antimicrobial silver ions into the surface of implantable medical devices to help reduce the incidence and severity of post-operative implant-related infection, and Acusure® plasma spray coatings designed to improve biocompatibility and durability of orthopaedic implants.
ACCENTUS With its corporate roots in
the UK Atomic Energy Authority, Accentus Medical is proud to be building a presence in the global medical device market from its operating base at the Harwell Campus. We have benefited from strong links with the local scientific and advisory support network in the Oxford region, and look forward to playing a part in the evolving HealthTec cluster at Harwell’
Harwell campus offers world leading research facilities, many opportunities to network, and various funding mechanisms to test new ideas and open the doors to new markets
22 23
adeliehealth.com
Adelie Health aims to understand problems faced by people with diabetes using insights from behavioural science. We design digital health solutions that fit seamlessly into the lives of people with diabetes. Empowering people to make small, meaningful adjustments that lead to big improvements.
ADELIE HEALTH
agamatrix.co.uk
AgaMatrix has developed the WaveSense JAZZ Wireless; a blood glucose meter that automatically syncs glucose results to the AgaMatrix App and enables patients to share their data with family members or healthcare professionals in just seconds.
AgaMatrix has been at the forefront of developing connected solutions for diabetes management and continues to take an innovative approach by working closely with Oxford University on further app developments.
AGAMATRIX Being located at the
prestigious Harwell Campus is vital for business development in terms of attracting and retaining employees, and links to the university for future innovation, in addition to creating a central hub that is within easy reach of the rest of the UK and Europe.
Alec WintonGeneral Manager, AgaMatrix EuropeCompany
Being at Harwell sets you in the heart of the ecosystem of the UK’s Science Vale, but most importantly gives access to the leading edge resources of the STFC both in terms of facilities such as the clean rooms and, more importantly, the people. For us this has decreased the cost of R&D but more importantly decreased the risk and accelerated timescales as well as promoting our visibility.
Mark Evans CEO, Adaptix
adaptiximaging.com
Adaptix is transforming planar X-ray – the most widespread diagnostic medical imaging modality.
The company aims to replace tubebased Victorian-era technology with an innovative Flat Panel X-ray source that will reduce costs to manufacture, deploy and maintain. The company is adding low-dose 3D capability – digital tomosynthesis – to planar X-ray, making it cheaper and truly portable so radiology can easily travel to the patient. Adaptix will deliver solid state 3D imaging at more affordable prices than conventional source based systems.
ADAPTIX
www.agilent.com
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Areas of expertise include Food, Environmental and Forensics, Pharmaceutical and Diagnostics, Chemical, Energy and Research.
01235 856555
AGILENT
24 25
aml.co.uk
AML manufactures unique in-situ Aligned Wafer Bonding systems, and provides services based around wafer bonding at its state-of-the-art multi-million pound Bondcentre facility located at Harwell.
01235 833934
APPLIED MICROENGINEERING
aurorahp.co.uk
Aurora is a leading independent UK provider of radiation protection services. From facility design to decommissioning, Aurora offers a comprehensive service with experience in all sectors. As the UK’s largest independent and fully accredited provider of radiation protection services we would be happy to support your needs relating to safety consultancy, radiological surveys, remediation, shielding integrity testing, emergency planning and waste assessment and disposal. Servicing the nuclear, life science, healthcare, aerospace and energy sectors, we have in depth of knowledge about the UK’s radiation protection market.
AURORA
cornerstoneoxford.co.uk
Cornerstone’s Steribot is taking a new approach to a robust and reliable long duty-cycle cleansing robot design developed for occupied clinical environments. Relentless and adaptive, Steribot targets the requirement for an easily integrated method of continuous, systematic risk reduction capable of continually treating many designated infection zones each and every day, whether people are present or not.
Cornerstone Oxford invites collaborations by design. We engage with partners through novel approaches to existing problems and fresh thinking discovery projects with significant impact potential for their enterprise. They in turn bring a critical infusion of scenarios and constraints. Cornerstone Oxford acts as a conduit between emerging technique, expertise, markets and challenges.
CORNERSTONE OXFORD LIMITED
borwell.com
Software solutions, artificial intelligence and systems integration experts tackle an array of industrial challenges from large scale satellite data, to cyber security, and life science imaging solutions.
BORWELL
dynamxmedical.com
DynamX Medical is a pioneering software company that combines infrared spectroscopy, disease biochemistry and artificial intelligence to extract more information from biological samples than ever before. When coupled with commercially available hardware, our novel analytical algorithms have the potential to be applied to a range of different diseases, improving diagnostic speed, shortening the time until treatment. DynamX Medical aims to improve the early diagnosis of numerous debilitating diseases by reducing the workload on expensive and invasive diagnostic pathways, easing the strain on an overburdened healthcare system.
DYNAMX MEDICAL
electrospinning.co.uk
Being on Harwell Campus provides us with the infrastructure and equipment to meet the high demands required of products designed for human implantation.
Ann KramerCEO, The Electrospinning Company
The Electrospinning Company designs, develops and manufactures advanced biomaterials for use in medical devices and regenerative medicine applications
The company offers services to translate electrospun scaffold innovations to scalable, clinic-ready products, and has established a pipeline of customer projects across a range of indications. They also manufacture the Mimetix® scaffold range for laboratory research, tissue engineering and stem cell applications, and supply a component of an FDA-approved device registered and sold in the USA that promotes endogenous tissue repair in orthopaedic surgery. Based in the Zephyr building, their R&D and manufacturing cleanroom facilities are ISO 13485 quality certified.
THEELECTROSPINNINGCOMPANY
26 27
e6.com
Element Six is a global leader in the design, development and production of synthetic diamond super-materials for industrial applications. Providing solutions for industries such as automotive and consumer electronics manufacturing, mining and road planning, and oil and gas drilling. Element Six is also opening up new applications synthetic diamond in a wide range of industries such as optics, power transmission, water treatment, semi-conductors and sensors.
“Element Six arrived at Harwell with over 100 R&D people four years ago and we have already engaged in six unexpected new exciting business collaborations with complementary technology groups across the campus.
An emerging area of research is the applications of nanodiamonds in life science industries, including drug delivery, bio-imaging, bio-sensor, and tissue engineering. Element Six is actively looking for partners in this field to enhance its research capacity, market exploration, and product development.”
Neill Hunt, Head of Innovation Projects Office, Element Six (a De Beers Group company).
ELEMENT 6
finden.co.uk
Finden offer advanced characterisation and analysis to help clients across sectors to develop and improve their products. We have applied techniques including X-ray absorption spectroscopy (XAS) and X-ray diffraction (XRD) to help confirm the chemical structures present in pharmaceuticals. The combination of these advanced techniques allows for identification of different polymorphs of chemicals based on both short- and long-range chemical structure in order to meet acceptance specification for new drug substances and new drug products (e.g. FDA Q6A).
FINDEN
gmv.com
GMV
helixtechnologies.co.uk
HELIX TECHNOLOGIES
aerospace.honeywell.com
HONEYWELL
i-emsat.co.uk
I-EM
GyreOx has engineered nature to create designer molecules to treat complex human diseases with unmet medical need, such as cancer, autoimmune diseases and inflammatory disorders. Our proprietary discovery platform creates unique and highly modified macrocyclic peptides called ‘gyrocycles’, which combine the target-engagement power of biologics with the cell-entry ability of small molecules. Gyrocycles are effective alternatives to therapeutic peptides.
Our combination of computational design, automation and unique engineered enzymes allows us to design and rapidly generate focused libraries of gyrocycles that can hit previously undruggable targets. Focussed library design enables better compound-target interaction and the tuning of important drug properties, including the key ability to pass through the human cell membrane and address drug targets inside.
GYREOX THERAPEUTICS LTD Our base at the Research Complex at Harwell provides access to state-of-the-art facilities and equipment to deliver the GyreOx mission, and to be close to the people and infrastructure that we need to be successful”
Bill PrimroseCEO, GyreOx Ltd.
28 29
karustherapeutics.com
Karus Therapeutics is a clinical-stage biopharmaceutical company, developing precision medicines for cancer. In our pipeline we have two experimental drug candidates, KA2507 and KA2237, and a preclinical research program focussed on next-generation, brain-penetrant, HDAC6 inhibitors for glioblastoma (brain cancer). We are seeking to help cancer patients with unmet medical needs and limited treatment options.
Currently (Jan 2020), we are concluding Phase I clinical studies for both of these drug candidates. Data for KA2237 shows an overall response rate of 37% in 19 evaluable patients with relapsed/refractory B cell lymphoma. KA2507 is being progressed into a Phase II clinical study in patients with advanced bile duct cancer at the CRUK-UCL Cancer Trials Centre in London.
Karus is part of the scientific community at the Harwell Campus in Oxfordshire, a leading UK Innovation Hub with excellent facilities, creating world-leading science and innovation.
KARUS THERAPEUTICS LTD.
us.mannatech.com/en-ukMannatech create some of the best nutritional supplements on the market and the science they have pioneered has grown, benefiting their product users.
MANNATECH
matthey.com
JOHNSON MATTHEYlaser-support.co.uk
LASER SUPPORT SERVICES LTD
lockheedmartin.com
LOCKHEED MARTIN
magnaparva.com
MAGNA PARVA
manifesthealth.co.uk
MANIFEST HEALTH LTD
kayserspace.co.uk
KAYSER SPACE
keit.co.uk
KEIT SPECTROMETERS
30 31
prpopto.com
PRP is in full control of every step of the design and manufacturing process. From their in-house fabs, through die-bonding, wire-bonding and packaging, designing the drive electronics, power management and digital circuit design, right up to the programming of firmware, embedded and control software. This offers a unique and flexible service that puts the customer’s needs at the heart of every custom design project, and a product range in which exceptional performance and reliability are built in from chip level upwards.
01793 881497
PRP OPTOELECTRONICS
nanoporetech.com
Oxford Nanopore Technologies Ltd is a private company employing 500 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. It is disrupting the paradigm of biological analysis by making high performance, novel, electronics-based DNA/RNA sequencing technology that is accessible and easy to use. This will enable the analysis of any living thing, by anyone, anywhere including real-time nanopore-based DNA/RNA sequencing technology that’s fully scalable for any requirement. Led by CEO Dr Gordon Sanghera, Oxford Nanopore Technologies, the company sells to almost 100 countries for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science and environmental research.
Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, education and a wide range of other applied uses.
OXFORD NANOPORE TECHNOLOGIES We are proud to manufacture our products in Harwell, one of the UK’s best centres of science.
Gordon SangheraCEO, Oxford Nanopore Technologies
medigold-health.com
MEDIGOLD HEALTH
oxhealthtechlabs.org
OXFORD HEALTHTEC LTD
quantumdetectors.com
QUANTUM DETECTORS
OXFORD CARE SENSE
oxford-micromedical.com
Oxford Micro Medical Ltd utilises technology originally stimulated by the Rosetta Space Mission to develop a novel mass spectrometer for healthcare applications.
Taking advantage of the facilities available through the ESA Business Incubation Centre, the company is developing an innovative technology for the detection of helicobacter pylori - a stomach infection that is linked to cancer. As this potentially life-threatening disease is more prominent in developing countries, Oxford Micro Medical are using the precision workshops at the Space Science facility at Harwell to develop a cheap, portable device that can be carried to remote areas.
OXFORDMICROMEDICAL
32 33
serralux.net
SerraLux is a global company focused on daylighting technologies designed to increase desirable, natural daylight for people inside buildings, living, learning, working and healing.
These technologies reduces energy consumption required by artificial lighting, and also manages and reduces glare, by better distributing the light from our windows.
The Helios Daylighting Research Program, supported by SerraLux, with academic and other organisations alongside, is based at Harwell.
The program utilises the Living Laboratory of this world-renowned technology campus, to develop digital tools to predict energy savings, using satellite-sourced weather data, and to undertake longitudinal studies to quantify health and productivity benefits of improved access to natural light in workplaces.
SERRALUX
midven.co.uk/company/ sfh-oxford-ltd
Since initial investment by UKI2S in 2013, the SFH team based at Harwell has been developing Graducheck, a sensor-based technology for improving the application of compression bandages for treatment of venous leg ulcers – a chronic wound that is a considerable burden; both for the patients and national healthcare systems. Venous leg ulcers affect over 12.5m patients globally and SFH Oxford’s application aims to massively increase treatment efficiency.
SFH OXFORD
resmed.com
RESMEDResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
ResMed UK Ltd has been based in Oxfordshire for 25 years and we are delighted to now be located on Harwell Science and Innovation Campus. From our new home we will continue to support the NHS and private patients through innovations, services, and solutions.
Harwell Campus is an exciting new chapter for ResMed UK. It provides our business with the ideal environment to continue our rapid growth and market leading position in the UK and Ireland.
Ewan CuthbertsonManaging Director, ResMed
rwm.nda.gov.uk
RADIOACTIVE WASTE MANAGEMENT LTD ricardo.com
RICARDO ENERGYAND EVIRONMENT
rheagroup.com
RHEA GROUP
34 35
36 37
new.siemens.com
SIEMENS
steris.com
STERIS is a leading provider of infection prevention and other procedural products and services. The company is focused primarily on healthcare, pharmaceutical and medical device Customers.
01235 443200
SYNERGY HEALTH PLC/STERIS
www.sihealth.co.uk
siHealth Ltd is an emerging company in the healthcare sector, developing cognitive mobile solutions for environmental health. The company has developed the very first satellite-based sun photoprotection technology (www.happysun.co.uk), supporting healthy lifestyle and skin diseases prevention in real-time through personal mobile apps. siHealth also provides innovative digital solutions for Artificial Intelligence-based smart diagnostics and for skin cancer telemedicine. siHealth is a member of both the Harwell HealthTec Cluster and the Harwell Space Cluster, collaborating with European Space Agency, UK Space Agency, STFC and Public Health England.
SIHEALTH We have been continually
supported by the creative and stimulating research environment at Harwell Campus, through its HealthTec and Space Clusters, enabling siHealth’s disruptive ideas to rapidly become ready-to-market solutions. Thanks to these results, BASF has recently invested in our company opening new perspectives for worldwide business and networking within the Campus.
Dr Emilio Simeone CEO, siHealth
36
HealthTec is an example of a regional cluster of national importance and reach. Clusters create critical mass within fields of endeavour shared by multiple organisations. Innovation occurs more readily where partners from different disciplines and sectors collaborate towards similar goals. Innovative R&D is being nurtured at Harwell, through the campus’ provision of support mechanisms, access to rare skills and facilities and active cross disciplinary communication and engagement mechanisms, such as the “Connect Harwell” initiative, cluster specific events and the development of field specific network organisations such as the Space Cluster and the HealthTec Cluster. In this way Harwell is making a unique contribution to the growth of both the UK’s science base and the national economy.
A strong example of positive life science/healthcare development is the HealthTec ‘proof of concept call’, which provided small amounts of feasibility funding to 12 successful proposals for the development of R&D. This ranged from the development of novel in situ X-ray diagnostic capabilities to 3D printing models of organic tissue, to a satellite-based real-time UV measurement system for personal health. Examples of cross disciplinary collaborations between organisations on and off site, which have emanated from HealthTec’s recent “Proof of Concept” (PoC) call include those between Lockheed Martin and MRC, SiHealth and PHE and Kayser Space and Harwell’s Central Laser Facility.
COLLABORATIVEADVANTAGE
12 successful
proposals for the development
of R&D
In the years ahead the Harwell HealthTec cluster, founded on multidisciplinary collaboration between physical and life sciences, will grow into a world-leading healthcare innovation hub focused on advanced therapeutics, preventative medicine and improving medical diagnosis and treatment through enhanced digital, e-health and remote healthcare capabilities.
Working with Harwell HealthTec Cluster has allowed Drayson Technologies to extend collaboration opportunities beyond environmental monitoring, in innovative digital health & multidisciplinary projects.
Dr Diana StefanHead of Sensor Technologies, Drayson Technologies
HealthTec has opened doors that allow us to design novel applications that can link Space technology to individual health benefits.
John AuburnStrategic Advisor, RHEA group
38
The treatment of disease is often hampered by a lack of understanding of the way in which complex biological processes influence the development of disease in individual patients. Being able to predict and monitor the progression of major diseases, and to use this information to develop “personalised medicine”, could offer improved outcomes for patients, whilst reducing costs for health services.
A £1.7m grant from the Medical Research Council (MRC) is bringing together the CLF, the Research Complex at Harwell (RCaH) and MRC Harwell to improve our understanding of diseases such as cancer, and other medical concerns such as deafness and ageing. The UK Astronomy Centre (UK ATC) in Edinburgh is also a collaborator, aiding in the development of adaptive optics for super-resolution microscopes. The development of adaptive optics solved a problem in astronomy research, where the ‘twinkling’ of stars (caused by atmospheric distortion) makes it hard to get a clear image. The murky environment within cells causes similar problems, and adaptive optics can help get a clear picture here as well.
CROSS-DISCIPLINARY WORKING
We have benefited from the experience and investment at Harwell that would have taken us years to develop alone. We felt part of the science community there and look forward to building our business in partnership with Harwell in the future.
Dr. Lee SmithAnglo Biopharma Ltd
Lockheed Martin is excited to be working with MRC Harwell to explore the prospects for medical research in Space, exploiting the potential of this growth area of the low Earth orbit economy. The HealthTec Cluster, with its broad range of capabilities, is an ideal place to develop innovative new ideas like this.
Stephen Gibson Head of Space, Lockheed Martin UK Ampthill
The HealthTec PoC funding has fundamentally enhanced the development of our product and company. It has provided the opportunity to work with a leading design agency and conduct in depth user research to provide a robust foundation for our ongoing growth.
Nick de PenningtonManaging Director, Head of Sensor Technologies, Ufonia
£1.7Mgrant from the medical
research council
CLF
38 39
HARWELLTOMORROW
The Harwell Science & Innovation Campus, 16 miles south of Oxford, covering 700 acres with 5,500 people across 200+ organisations has embarked upon an ambitious expansion plan with millions of square feet of new working & research space. Importantly this will be supported by hundreds of new homes targeted at people working on site together with improved on site amenities.
Within this overall masterplan, during 2020 planning permission will be sought for a new 750,000 sq ft expansion of the life science/HealthTec cluster sited close to the major facilities at its core.
There are many options available for the entire spectrum of SME’s to major multi-nationals looking to relocate to Harwell. We have the flexibility to offer highly cost effective space within new buildings or bespoke new buildings with planning in place; or for larger groups the ability to create your own “Campus on a Campus” with land reserved alongside for future expansion.
The ambition of the Harwell Campus expansion is matched only by that of the many brilliant researchers and scientists who call the Harwell Campus home.
MILLIONSmore square feet of new buildings
TENS of thousands
of people
NEW PUBLIC realm and campus
amenities
HUNDREDS of new homes
ENTERPRISEZONE
benefits
40
MAJOR CURRENT AND FUTURE BUILDING PROJECTS• Expanding life science/
HealthTec cluster – 750,000 sq ft
• Rosalind Franklin Institute
• Vaccines Manufacturing and Innovation Centre
• Extreme Photonics Application Centre
• Major Current and Future Building Projects section to ‘Hundreds of new homes offering affordable housing to rent or buy at Harwell, enabling people to work and live here
NEW AMENITIES• Gym
• Café
• Work pod ‘hides’ in a newly landscaped water feature area
BESPOKE DESIGN & BUILD• From 20,000 sq ft
HARWELL CAMPUS DEVELOPMENTS • Over 300,000 sq ft being developed
• R&D space, offices and laboratories
• Units available from 2,000 sq ft
[email protected]+44 (0) 1865 592632
Lambert Smith [email protected]+44 (0) 1865 200244
To enquire, please contact:
• Suitable for R&D, offices, laboratory, clean room, light engineering and production• Flexible unit sizes from 278 sq m (3,000 sq ft) to 2,787 sq m (30,000 sq ft) Gross Internal Area
ZEUSBUILDINGBrilliance Every Day
New R&D Space, Offices and Laboratories
Remaining Units – New R&D Space, Offices, Laboratories & Engineering
30/10/2015 15:05
HarwellCampus.com HarwellHub.com @HarwellCampus +44 (0) 1235 250091
01865 200 244
40 41
LIFE AT HARWELL
Venture
INVESTMENT, FUNDING SOURCES AND BUSINESS SUPPORTOxfordshire is the best region of the UK for emerging life science/HealthTec companies to raise funds.
Harwell lies at the heart of the Oxfordshire-Thames Valley region which is one of the largest life science clusters in Europe with around 650 life science companies across pharma, biotech, diagnostics, medtech and digital health.
Many of the most important investors into emerging life science companies are local:
Invesco Perpetual and Oxford Sciences Innovation.
Other close investors include:
Novo, SV Life Sciences, IP Group, Lansdowne Partners, Wellcome Trust, Oxford Capital Partners, Longwall Venture Partners, Rainbow Seed Fund and UKI2S.
Business support is provided via proactive business development initiatives to link companies to the “open access” science facilities on site as well as to other complimentary technology companies through “Connect Harwell” and with the NHS through our close partnership with the Oxford Academic Science Network.
FUNDRAISING BY LOCATIONSource: E&Y
The Harwell Campus partnership exists to provide you not only with the perfect, cost-effective, property solution but also is here to help you access funding faster and to open doors to new value – add commercial partners and technologies.
Gordon DuncanPartner, Harwell Campus
Oxfordshire & Thames Valley
Valu
e ($
m) p
er lo
catio
n
500
1,000
1,500
2,000
London Cambridge & East Anglia
Other regions
DebtFollow-onIPO
SUPERBTRAVELLINKS
A34
A34
HEATHROW
DIDCOT PARKWAY
STANSTED
BIRMINGHAM
GATWICK
BRISTOL
LUTON
SWINDONREADING
Harwell
LONDON
CAMBRIDGE
OXFORD
M25
M40
A1(M)
M11
M6 TOLL
M3
M4
M4
M5
M5
M6
A1
M1
M3
M25
M25
43MINUTES TRAIN
RIDE TO LONDON
40MINUTES DRIVE TO
HEATHROW AIRPORT
25MINUTES DRIVE
TO OXFORD
The map shown is not to scale and all times quoted are approximate with rail times from Didcot Parkway Station. Sources: Nationalrail.co.uk; google.co.uk; Crossrail.co.uk.
Travelling to and from Harwell Campus is easy. Next to the A34 the Campus lies just 16 miles from Oxford, offering easy access to the UK’s two largest cities – London and Birmingham – via the M40 and M4 motorways. It is also less than a forty minute drive from London Heathrow Airport, the UK’s premier hub airport.
Heathrow will be faster by rail with the addition of Crossrail in 2018, as well as quicker journeys to other areas of London.
Frequent direct trains from nearby Didcot Parkway station take around 45 minutes to London Paddington or Bristol Temple Meads and 15 minutes to Reading.
The Campus has its own bus station with direct links to Didcot (including Didcot Parkway), Wantage, Abingdon, Oxford, Newbury and surrounding towns and villages. A new express Science Shuttle has recently been introduced for staff and visitors travelling between the University of Oxford Campus and Harwell.
ACCESSANDPARKINGAll buildings are easily accessible by road, with parking adjacent and nearby.
4544 45
Whether you are interested in a small 5,000 sq ft local team office or 500,000 sq ft bespoke offices, laboratories and production facilities, the Campus team at the Harwell Management Office would be delighted to talk to you about how Harwell can contribute to your success.
We can help you to engage the skilled people that you need, discuss how to access the scientific equipment and knowledge at Harwell, and tell you everything you need to know about moving to our world-class science and innovation campus.
The best way to appreciate the breadth and depth of the facilities and opportunities at Harwell Campus is to visit us.
VISIT US
46
harwellcampus.com twitter.com/HarwellCampus
Angus [email protected]
CONTACTS
Dr Barbara [email protected]
Dr Adrian [email protected] +44 (0) 1235 446575
Gordon [email protected]
Harwell Management OfficeHQ Building, Thomson Avenue, Harwell Campus,Didcot, Oxfordshire, OX11 0GDGeneral enquiries: + 44(0) 1235 250091
46 47
harwellcampus.com twitter.com/HarwellCampus
